Chugai Pharmaceutical

Update in progress

4519.T (Tokyo)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Chugai Pharmaceutical Co., Ltd., with its subsidiaries, conducts research, development, manufacture, and sale of medicines in Japan and worldwide. It offers oncology drugs such as Alecensa, Avastin, Kadcyla, Tecentriq, Herceptin, Phesgo, Perjeta, Lunsumio, Polivy, FoundationOne; Actemra for IL-6 receptor; CellCept; Enspryng; Evrysdi; Hemlibra; Mircera; PiaSky; Tamiflu; and Vabysmo. Founded 1925, renamed 1943, based in Chuo, Tokyo, and a Roche subsidiary.

Company score

Sentiment: 0.34; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.31; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.19; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.27; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive